Phaseline

Targets › LHR

LHR (CD44 antigen): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 4, 1 Phase 3; Genitourinary; next expected readout Aug 2027.

Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment. Participates thereby in a wide variety of cellular functions including the activation, recirculation and homing of T-lymphocytes, hematopoiesis, inflammation and response to bacterial infection. (UniProt, P16070)

Open in Phaseline: the race on LHR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Fundación Santiago Dexeus FontrhFSH+rhLH (Pergoveris®)
Recombinant human follicle-stimulating hormone and recombinant human luteinizing hormone
FSHR, LHRPhase 4InfertilityAug 2027
Granata BiohMG (human menopausal gonadotropin)
Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) receptor agonist
FSHR, LHRPhase 3Infertility (IVF Patients)Nov 2028

Conditions

Infertility (2) Infertility (IVF Patients) (1)

Modalities

small molecule (2)

Companies

Fundación Santiago Dexeus Font (1) Granata Bio (1)

Related targets

FSHR (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.